Abstract:Type 1 diabetes (T1D), which prevalence is currently on the rise, is a major risk factor for cardiovascular disease (CVD). Although T1D induces endothelial dysfunction, a precursor and contributor to CVD, its etiology remains ill-defined. Aberrant increases in endothelial cell (EC) glycolysis mainly via increased expression/ activity of its regulatory enzyme, 6-phosphofructo-2- kinase/fructose-2, 6-bisphosphatase 3 (PFKFB3) contribute to several vascular disorders. Nevertheless, whether alterations in EC glycolysis impairs endothelium dependent relaxation (EDR) is unknown. Using Akita mice, a genetic model of T1D, and a newly developed assay to measure EC glycolytic capacity in aortic explants via Seahorse analyzer, we tested the hypothesis that T1D impairs endothelial function via increasing EC glycolysis. Aortic explants from Akita mice exhibited a 1.7-fold increase in glycolysis to WT (P<0.05). EC-denudation abolished these increases which identify EC as the source of increased vascular glycolysis. These metabolic changes were accompanied by a 2-fold increase in EC PFKFB3 expression in aortas of Akita mice and inhibition of PFKFB3 using 3PO restored EDR in Akita mice. Interestingly, increases in EC glycolysis in situ via transduction of adenoviral vectors to overexpress either PFKFB3 (Ad-PFKFB3) or a constitutively active form of PFK2 to drive glycolysis independent of PFKFB3 (Ad-GlycoHi) reproduced the endothelial dysfunction associated with T1D. Also, EC transduced in vitro with Ad-PFKFB3 depicted increased expression of the ROS–producing enzyme, NADPH oxidase homolog, Nox1, and its co-activator, NoxA1(p<0.05). Similarly, aorta EC from Akita mice revealed increased Nox1 and NoxA1 expression. Inhibition of Nox1 fully restored EDR in Akita and Ad-PFKFB3-transduced WT aortas. Consistently, aortas from Nox1 KO mice were protected from Ad-PFKFB3-induced endothelial dysfunction. T1D markedly increased the aortic expression of the Advanced Glycation End products (AGE) precursor methylglyoxal (MG) (p<0.05), thus, we tested the contribution of AGE to T1D-induced EC glycolysis. Aortic rings exposed to MG showed increased EC PFKFB3 and Nox1 expression and impaired EDR. The latter was restored in rings incubated with 3PO or in rings from EC-specific PFKFB3 deficient mice (p<0.05). Also, T1D and exposure to MG upregulated hypoxia-inducible factor 1α(HIF1α) expression in EC. HIF1α inhibition blunted MG-mediated PFKFB3 upregulation in aorta EC (p<0.05). In Conclusion, this study identified for the first time a role for endothelial PFKFB3-mediated glycolysis in T1D-induced endothelial dysfunction. The underlying mechanism involves AGE and HIF1α as upstream regulators and NOX1 as a downstream target for PFKFB3. Thus, PFKFB3 and Nox1 inhibitors are potential therapeutic targets for diabetes-induced vascular complications. R01s (1R01HL147639-01A1 and 1R01HL155265-01) and 19EIA34760167 to E.J. Belin de Chantemèle. APS APHYS00010 and 2020AHA000POST000204982 to R.T.Atawia This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

D-β-Hydroxybutyrate Dehydrogenase Mitigates Diabetes-Induced Atherosclerosis through the Activation of Nrf2

Autophagy protects against senescence and apoptosis via the RAS-mitochondria in high-glucose-induced endothelial cells.

A Novel Protective Mechanism for Mitochondrial Aldehyde Dehydrogenase (aldh2) in Type I Diabetes-Induced Cardiac Dysfunction: Role of Ampk-Regulated Autophagy

BDH1-mediated βOHB metabolism ameliorates diabetic kidney disease by activation of NRF2-mediated antioxidative pathway

Epigenetically Altered Macrophages Promote Development of Diabetes-Associated Atherosclerosis

Arginase Inhibition Prevents Vascular Endothelial Dysfunction in a Type 2 Diabetes Model (1139.13)

Targeting the KCa3.1 channel suppresses diabetes-associated atherosclerosis via the STAT3/CD36 axis

Hydrogen Sulfide Induces Keap1 S-Sulfhydration and Suppresses Diabetes-Accelerated Atherosclerosis Via Nrf2 Activation

Type 1 Diabetes Impairs Vascular Relaxation Via Increases in Endothelial Glycolysis and Activation of the HIF1a-PFKFB3-Nox1 Pathway in Mice.

DMDD, isolated from Averrhoa carambola L., ameliorates diabetic nephropathy by regulating endoplasmic reticulum stress-autophagy crosstalk

Dendritic cell-mediated chronic low-grade inflammation is regulated by the RAGE-TLR4-PKCβ1 signaling pathway in diabetic atherosclerosis

Activation of AMPK/miR-181b Axis Alleviates Endothelial Dysfunction and Vascular Inflammation in Diabetic Mice

1334-P: Hepatocyte D-ß-Hydroxybutyrate Dehydrogenase Deficiency Improves Glucose Homeostasis and Prevents Diet-Induced Liver Fibrosis

Suppression of Excessive Histone Deacetylases Activity in Diabetic Hearts Attenuates Myocardial Ischemia/Reperfusion Injury Via Mitochondria Apoptosis Pathway

miR-369-3p ameliorates diabetes-associated atherosclerosis by regulating macrophage succinate-GPR91 signaling

Soluble Epoxide Hydrolase Inhibition Protected Against Diabetic Cardiomyopathy Through Inducing Autophagy and Reducing Apoptosis Relying on Nrf2 Upregulation and Transcription Activation.

PPAR-α Agonist Fenofibrate Prevented Diabetic Nephropathy by Inhibiting M1 Macrophages via Improving Endothelial Cell Function in db/db Mice

High glucose levels accelerate atherosclerosis via NLRP3-IL/ MAPK/NF-κB-related inflammation pathways

Mitochondrial Aldehyde Dehydrogenase Obliterates Insulin Resistance-Induced Cardiac Dysfunction Through Deacetylation of PGC-1α

Integrated multi-omic high-throughput strategies across-species identified potential key diagnostic, prognostic, and therapeutic targets for atherosclerosis under high glucose conditions

Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation